DENA LOWE: Open Payments
NPI 1356035752 · NEW IBERIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,872 in 86 payments from 28 companies in 2025. Trend: 2023 $376 · 2024 $1,930 · 2025 $1,872
Food & beverage: $1,872
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 9 | $304 |
| AstraZeneca Pharmaceuticals LP | 12 | $267 |
| Novartis Pharmaceuticals Corporation | 7 | $153 |
| Eisai Inc. | 11 | $149 |
| PFIZER INC. | 6 | $122 |
| Stemline Therapeutics Inc. | 4 | $92 |
| Merck Sharp & Dohme LLC | 3 | $70 |
| Celgene Corporation | 3 | $62 |
| Ipsen Biopharmaceuticals, Inc | 3 | $62 |
| GlaxoSmithKline, LLC. | 3 | $55 |
Products named: RYBREVANT, Lenvima, CALQUENCE, Orserdu, TALVEY, KEYTRUDA, LYNPARZA, REBLOZYL.
Industry payments across LA — which companies pay providers there.
